Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/29/2007WO2007135083A1 Preparations for sebum reduction with a content of hydroxycitrate as active principle
11/29/2007WO2007135081A1 Histamine receptor antagonists comprising an azepin core
11/29/2007WO2007135080A2 (2r)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them
11/29/2007WO2007135027A1 Substituted pteridines substituted with a four-membered heterocycle
11/29/2007WO2007135024A1 New long-acting drug combinations for the treatment of respiratory diseases
11/29/2007WO2007134986A1 Pyridopyrimidinone derivatives
11/29/2007WO2007134968A1 Inhalant aerosol formulations containing ethanol
11/29/2007WO2007134967A1 Propellant-free inhalation aerosol formulation containing ipratropium bromide and salbutamol sulfate
11/29/2007WO2007134966A1 Inhalant propellant-free aerosol formulation
11/29/2007WO2007134965A1 Aerosol formulation containing ipratropium bromide and salbutamol sulfate
11/29/2007WO2007134964A1 Novel medicament combinations for the treatment of respiratory diseases
11/29/2007WO2007134958A1 Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
11/29/2007WO2007134870A1 Bilayer tablet for preventing cardiovascular events
11/29/2007WO2007134868A2 3,5-dihydroxy-2,4-cyclohexadienones and their derivatives, dietary compositions and fortified food containing them and their uses
11/29/2007WO2007134867A2 Treating muscular disorders and improving muscular function
11/29/2007WO2007134864A1 Indole derivatives and their use as thyroid receptor ligands
11/29/2007WO2007134862A1 Substituted arylimidaz0l0ne and triaz0l0ne as inhibitors of vasopressin receptors
11/29/2007WO2007134845A2 Olanzapine pharmaceutical composition
11/29/2007WO2007134828A1 Pyrazolo [3, 4-d] pyrimidine derivatives useful to treat respiratory disorders
11/29/2007WO2007134827A1 5-phenyl-thiaz0l-2-yl-urea derivatives and use as pi3 kinase inhibitors
11/29/2007WO2007134819A1 Cationic liposomal preparations for the treatment of rheumatoid arthritis
11/29/2007WO2007134709A1 5-iodotetrazoles for use as antimycotic
11/29/2007WO2007134678A2 Triazole derivatives ii
11/29/2007WO2007134677A1 1,5-diphenylpyrazoles ii as hsp90 inhibitors
11/29/2007WO2007134625A1 New benzothiazinone derivatives and their use as antibacterial agents
11/29/2007WO2007134595A2 Novel formulation, oriented to tumour physiology, of a cytostatic, in particular of cis-platinum
11/29/2007WO2007134578A1 Novel indol-pyrrol derivatives for the treatment of proliferative and inflammatory diseases
11/29/2007WO2007134534A1 WATER SOLUTION OF 20(R)-GINSENOSIDE Rg3 PHARMACEUTICAL COMPOSITION AND PROCESS THEREOF
11/29/2007WO2007134533A1 20(R)-GINSENOSIDE Rg3 MEDICINAL SOLUBLE INTERMEDIATE AND PROCESS THEREOF
11/29/2007WO2007134485A1 Aporphine and oxoaporphine compounds and pharmaceutical use thereof
11/29/2007WO2007134457A1 Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
11/29/2007WO2007134451A1 Oligonucleotides affecting expression of phosphodiesterases
11/29/2007WO2007134449A1 Screening methods for amyloid beta modulators
11/29/2007WO2007134434A1 Phenanthrene derivatives as mpges-1 inhibitors
11/29/2007WO2007134362A1 2-ARYLPYRAZOLO[L,5-α]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA)
11/29/2007WO2007134354A1 Pharmaceutical formulation
11/29/2007WO2007120760A3 Thiophene-carboxamides useful as inhibitors of protein kinases
11/29/2007WO2007120647A3 Compositions useful as inhibitors of voltage-gated sodium channels
11/29/2007WO2007120599A3 Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
11/29/2007WO2007117563A3 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and use thereof
11/29/2007WO2007117559A3 Renin inhibitors
11/29/2007WO2007117557A3 Diaminopropanol renin inhibitors
11/29/2007WO2007115409A8 Compositions and methods for modulating gated ion channels
11/29/2007WO2007115287A3 Combination of organic compounds
11/29/2007WO2007114949A8 Securing apparatus and method
11/29/2007WO2007114945A3 Compositions and methods for enhancing the antioxidant status of animals
11/29/2007WO2007114855A3 Glucagon receptor antagonists, preparation and therapeutic uses
11/29/2007WO2007113841A3 Novel aminoglycosides and uses thereof in the treatment of genetic disorders
11/29/2007WO2007113558A3 Quinazolinone derivatives having b-raf inhibitory activity
11/29/2007WO2007113269A3 15-desmethoxymacbecin derivatives for the treatment of cancer diseases
11/29/2007WO2007113249A3 N-hydroxy-3-(4-{3-phenyl-s-oxo-propenyl}-phenyl)-acrylamide derivatives and related compounds as histone deacetylase inhibitors for the treatment of cancer
11/29/2007WO2007113222A3 Immunogenic composition
11/29/2007WO2007112914A3 Ceramide kinase modulation
11/29/2007WO2007112073A3 Methods for modulating bladder function
11/29/2007WO2007111880A9 Intranasal administration of ketamine to treat depression
11/29/2007WO2007110705A3 Macrolide as inhibitors of mhc class ii
11/29/2007WO2007110047A3 TERGURIDE/PROTERGURIDE FOR THE TREATMENT OF CHRONIC PAIN (e.g. MIGRAINE)
11/29/2007WO2007109615A3 β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
11/29/2007WO2007109547A3 Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
11/29/2007WO2007108968A3 Ophthalmic compositions for treating ocular hypertension
11/29/2007WO2007106537A3 Aminoquinolones as gsk-3 inhibitors
11/29/2007WO2007106349A3 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
11/29/2007WO2007104780A3 N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use
11/29/2007WO2007103931A3 Nanofluidized b-12 composition and process for treating pernicious anemia
11/29/2007WO2007103149A3 Treatment of atherosclerotic disease
11/29/2007WO2007103114A3 Notch inhibition in the treatment or prevention of atherosclerosis
11/29/2007WO2007101148A3 Hexose compounds to treat cancer
11/29/2007WO2007100758A3 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
11/29/2007WO2007100466A3 Nanoparticulate carvedilol formulations
11/29/2007WO2007100366A3 Quinolone m1 receptor positive allosteric modulators
11/29/2007WO2007099162A3 Hydroxylated long-chain resveratrol derivatives useful as neurotrophic agents
11/29/2007WO2007098964A3 Pyrrazole derivatives as sigma receptors antagonists
11/29/2007WO2007095630A3 New ubiquinone analogs and methods of use
11/29/2007WO2007095342A3 Stable corticosteroid mixtures
11/29/2007WO2007094886A3 One pot synthesis of tetrazole derivatives of sirolimus
11/29/2007WO2007093184B1 Treatment of mmp-mediated dermatological diseases with pemirolast
11/29/2007WO2007092741A3 Hydroxylamines and derivatives as anti-angiogenic agents
11/29/2007WO2007090836A3 Piperidine derivatives as cxcr3 receptor antagonists
11/29/2007WO2007090749A3 Benzamide and heteroarene derivatives as cetp inhibitors
11/29/2007WO2007090255A3 Polymeric implant and a process for obtaining a polymeric implant
11/29/2007WO2007089735A3 Potassium channel inhibitors
11/29/2007WO2007087609A3 Formulations and methods for treating dry eye
11/29/2007WO2007087056A3 Peramivir derivative for oral administration
11/29/2007WO2007086884A3 Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
11/29/2007WO2007085629A3 Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
11/29/2007WO2007084998A3 Compositions comprising kakadu plum extract or acai berry extract
11/29/2007WO2007084875A3 Spiro compounds and methods of use
11/29/2007WO2007084648A3 Mixed 4→6 procyanidin dimers and their use
11/29/2007WO2007084542A3 Treatment of inflammatory disorders with triazole compounds
11/29/2007WO2007084473A3 The use of memantine and brimonidine to attenuate vitreoretinal vascular endothelial growth factor (vegf) protein levels in animals
11/29/2007WO2007084413A3 Methods for treating hepatitis c
11/29/2007WO2007080116A3 Use of cns penetrating anticancer compounds for the treatment of protozan diseases
11/29/2007WO2007079139A9 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
11/29/2007WO2007078335A3 Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
11/29/2007WO2007076423A3 INHIBITORS OF Akt ACTIVITY
11/29/2007WO2007076320A3 Compounds
11/29/2007WO2007076286A3 Chemical compounds
11/29/2007WO2007076159A3 Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
11/29/2007WO2007075895A3 Heterocyclic derivatives as modulators of ion channels
11/29/2007WO2007075869A3 Bicyclic heteroaryl compounds
1 ... 3479 3480 3481 3482 3483 3484 3485 3486 3487 3488 3489 3490 3491 3492 3493 3494 3495 3496 3497 3498 3499 ... 7860